Open Pharma position statement on open access

Pharmaceutical companies, which fund approximately half of all biomedical research,[1] are now leaders in the publication and disclosure of research.[2,3] However, access to much company-funded research is restricted by journal paywalls.[4] We, as Open Pharma, a group of pharmaceutical companies and other research funders, alongside healthcare professionals, regulators, patients, publishers and other stakeholders in healthcare, recognize the importance of publishing research with open access, where papers can be read without payment of a one-off access charge or subscription. Open access ensures that the highest quality, peer-reviewed evidence is available to anyone who needs it, anywhere in the world. Publishing with open access improves transparency, advances medical science and, we believe, ultimately improves patient care.

Our immediate priority

Our immediate priority is to secure authors publishing company-funded research the same right to publish open access as authors publishing research funded by other sources, so that all research can be made free to read from the date of publication. This would enable pharmaceutical companies to follow the lead of other research funders in requiring all the research they fund to be published with open access, without impacting on journal choice.[5-7] In order to provide publishers the time to adapt their policies and protect their copyright interests, any variant of Creative Commons or equivalent licence could be used.

Our long-term goal

Our long-term goal is to secure authors publishing company-funded research the same terms as authors publishing research funded by other sources, so that all research can be made free to read – and reuse – from the date of publication. This would enable pharmaceutical companies to follow the lead of other research funders in maximizing the impact of the research they fund on patient health. Open Pharma is committed to working closely with publishers and pharmaceutical companies to ensure that the gold standard Creative Commons Attribution (CC BY) licence can sustainably be used.[8]

Acknowledgements

References

1. Dorsey ER, de Roulet J, Thompson JP *et al.* Funding of US biomedical research, 2003–2008. *JAMA* 2010;303:137–43.
2. Baronikova S, Purvis J, Southam E *et al.* Commitments by the biopharmaceutical industry to clinical trial transparency: the evolving environment. *BMJ Evidence-Based Medicine* 2019:bmjebm–2018–111145.
3. Warren M. Big pharma is embracing open-access publishing like never before. Nature, 2019. Available from: https://www.nature.com/articles/d41586-019-00610-2 (Accessed 3 October 2019).
4. Ellison TS, Koder T, Schmidt L, Williams A, Winchester CC. Open access policies of leading medical journals: a cross-sectional study. *BMJ Open* 2019;9:e028655.
5. Collins E. Publishing priorities of biomedical research funders. *BMJ Open* 2013;3:e004171.
6. Baronikova S, Desai SY, Philippon V, Rains CP. An assessment of open access publishing at Shire before and after implementation of the open access publication policy. *Curr Med Res Opin* 2019;35(Suppl 2):31.
7. Lang H, Winchester CC, Gattrell W. Open access publishing of research affiliated to Ipsen, 2013–2017: a baseline assessment. *Curr Med Res Opin* 2019;35(Suppl 2):39.
8. Tennant JP, Waldner F, Jacques DC *et al.* The academic, economic and societal impacts of Open Access: an evidence-based review. *F1000Res* 2016;5:632.

Endorsements

Publishers

Betasciencepress Publishing

*E*cancer

F1000 Research Ltd.

Frontiers Media SA

Future Science Group

Wiley

Organizations

Ataxia & Me

Autoinflammatory UK

Cambridge Rare Disease Network

Galapágos NV

International Kidney Cancer Coalition

Ipsen

Kidney Research UK

Observational and Pragmatic Research Institute Pte

Oxford Health Policy Forum

Oxford PharmaGenesis

Pedalling4ACure

Solanum Medical Communications Ltd.

SUDEP Action

The Aarskog Foundation

ThinkSCIENCE, Inc.

Zimbabwe Evidence Informed Policy Network

Individuals

Mary Kunjappu, Alexion Pharmaceuticals

Kenneth Pomerantz, Alexion Pharmaceuticals

Alan Thomas, Ataxia & Me

Scott Armit, Ataxia & Me

John Wallace, Autoinflammatory UK

Gavin Giovannoni, Barts and the London School of Medicine and Dentistry

Roland J.W. Meesters, Betasciencepress Publishing

E. Andrew Balas, Biomedical Research Innovation Laboratory, Augusta University

Val Tate, communications consultant

Raj Kadadai, Cure SCA3

Brian S. Alper, EBSCO Information Services

https://doi.org/10.6084/m9.figshare.10003304

Katie Foxall, *ecancer*

Linda Edmonson, Innovative Strategic Communications

Tim Day, Innovative Strategic Communications

Martin Delahunty, Inspiring STEM

Alben Sigamani, Narayana Health

Michael De Rosa, National Ataxia Foundation

Peter Llewellyn, NetworkPharma Ltd.

Pali Hungin, Newcastle University

Klaus Boberg, Novo Nordisk

Heather Piwowar, Our Research

Serena Vanzan, Oxford Brookes University

Kajsa Wilhelmsson, Oxford Health System Reform Group

Adele Buss, Oxford PharmaGenesis

Alison Hillman, Oxford PharmaGenesis

Cassy Fiford, Oxford PharmaGenesis

Emma Bolton, Oxford PharmaGenesis

Francesca Ounsworth, Oxford PharmaGenesis

Jessica Hardy, Oxford PharmaGenesis

Julie Beeso, Oxford Pharmagenesis

Mark Rolfe, Oxford PharmaGenesis

Nicolas Bertheleme, Oxford PharmaGenesis

Paul Farrow, Oxford PharmaGenesis

Richard White, Oxford PharmaGenesis

Sally Bardell, Oxford PharmaGenesis

Sarah Sabir, Oxford PharmaGenesis

Steph Macdonald, Oxford PharmaGenesis

Tamzin Gristwood, Oxford PharmaGenesis

Tim Ellison, Oxford PharmaGenesis

Tim Koder, Oxford PharmaGenesis

Zoe Watts, Oxford PharmaGenesis

Graham Shelton, Oxford University Hospitals Foundation

Charles Boyce, patient

Emily Medina, patient

Jeannie Smithball, patient

Danielle Grover, patient advocate

Elizabeth Kinder, patient advocate

Richard Stephens, patient advocate

Tracy Zervakis, patient advocate

Trishna Bharadia, patient advocate

Rosario Strano, Pedalling4Cure

Angela Sykes, Pfizer

Courtney Leo, Pfizer

J.R. Meloro, Pfizer

Ellie Challis, PTEN UK & Ireland

Dermot Ryan, Respiratory Effectiveness Group

Sophie Berry, Smith & Nephew

John Gonzalez, Solanum Medical Communications Ltd.

Laura Paglione, Spherical Cow Group

Jane Hanna, SUDEP

Raquel Billiones, Takeda Vaccines

Victoria Woods, Patient and Public Engagement, Thames Valley Cancer Alliance at NHS England

Zbys Fedorowicz, The Care Combine and North West Anglia NHS Foundation Trust

Stuart Taylor, The Royal Society

Caryn Jones, THINK Science

John Pernick, THINK Science

Erik Michels, UCB

Rachel Giles, Regenerative Medicine Center, UMC Utrecht

Meredith Hays, Department of Medicine, Uniformed Services University

Martin Rossor, University College London

Stephen Bradley, University of Leeds

Robert Sim, Department of Respiratory Science, University of Leicester

Iain Chalmers, Centre for Evidence-Based Medicine, University of Oxford

Edith Sim, Department of Pharmacology, University of Oxford

Chas Bountra, Nuffield Department of Clinical Medicine, University of Oxford

Stevan Harnad, University of Southampton

Álvaro Díaz, Departamento de Biociencias, Universidad de la República, Uruguay

Ronald Munatsi, Zimbabwe Evidence Informed Policy Network

Endorsements last updated on 27 February 2020